What Every Small Biotech Needs to Know: Partnering & Drug Discovery Advice from Repligen & Aphios

Thursday, February 21 2013
8:00 am – 10:00 am

Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA

7:30am-8:30am: Networking & Breakfast


James Rusche, Senior Vice President, Research & Development at Repligen will discuss:

Partnering Translational Research in CNS From a Small Biotech Platform

Repligen has worked to develop oral small molecule drugs to modulate expression in single gene orphan diseases in the neurodegenerative disease space. Preclinical and clinical development of candidate drugs in Friedreich's ataxia and spinal muscular atrophy provide potential for endogenous protein replacement in diseases with no current treatments. The financial requirements of program development in a small company environment can be managed through collaborations with disease stakeholders to achieve a productive exit point.  

Trevor P. Castor, President & CEO, Aphios Corporation, will present:

Corporate History, Business Model, Technology Platforms and Therapeutic Products

Aphios® Corporation (www.aphios.com), Woburn, MA, a clinical-stage biotechnology company, is developing enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety.  Using these enabling technology platforms, Aphios and its collaborators are developing enhanced therapeutics for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders such as Alzheimer’s disease.


10:30am: As this event concludes, you are invited to join Basel Day: A Global Gateway Event


Speaker Bios

James R. Rusche, Ph.D., joined Repligen in March 1996 as Vice President, Research and Development in connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. In 2001, Mr. Rusche became Senior Vice President, Research and Development. From July 1994 to March 1996, Mr. Rusche was Vice President, Research and Development of Glycan Pharmaceuticals, Inc. From February 1985 to June 1994, he held numerous research positions at Repligen, most recently as Vice President, Discovery Research. Mr. Rusche holds a B.S. in microbiology from the University of Wisconsin, LaCrosse and a Ph.D. in immunology from the University of Florida.

Trevor P. Castor, Ph.D., President and Chief Executive Officer, has over 30 years of diversified business experience ranging from management, marketing and finance to technology and business development in the energy, environmental and biopharmaceutical industries. He has had bottom-line experience with several high-tech startups. Dr. Castor graduated from the University of California, Berkeley, with a Ph.D. in Mechanical Engineering and a Master of Science degree in Chemical Engineering. He graduated summa cum laude with a Bachelor of Science degree in Chemical Engineering from the University of Toronto, Toronto, Canada. He studied Business Administration at St. Mary's College, Brooklyn, NY, and Management, Marketing and Finance at the Harvard University Extension Program, Cambridge, MA. He is the primary author of 36 issued US and international patents and 15 pending patents. Dr. Castor has collaborated with and consulted to several multinational companies including Baxter Healthcare, Bayer AG, Bristol-Myers Squibb, Eli Lilly, General Electric, Novartis AG and the Gillette Company, and financial institutions such as the Bank of New England and the New England Life Insurance Company.

Share MassBio